Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.41 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.38 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.38 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.37 |
| ▸ | MGAM | O43451 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | SI | P14410 | 2/20 | 0.37 |
| ▸ | MGAM2 | Q2M2H8 | 2/20 | 0.37 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5881759 | 0.88 | PTGS2 (0.46) | MAPTPTGS2HDAC3HDAC4HDAC1 | |
| SCHEMBL5881768 | 0.85 | FLT1 (0.51) | MAPTPTGS2HDAC3HDAC4HDAC1 | |
| SCHEMBL6327748 | 0.85 | PPARG (0.41) | MAPTPTGS2HDAC1MCL1CSF1R | |
| SCHEMBL6320276 | 0.84 | PTGS2 (0.41) | MAPTPTGS2KAT6AHDAC3HDAC4 | |
| SCHEMBL6319512 | 0.83 | MGAM (0.43) | MAPTPTGS2HDAC3HDAC4HDAC1 | |
| SCHEMBL5881622 | 0.83 | MAPT (0.46) | MAPTPTGS2KAT6AHDAC3HDAC4 | |
| SCHEMBL6321295 | 0.83 | PTGS2 (0.43) | MAPTPTGS2HDAC3HDAC4HDAC1 | |
| SCHEMBL6322418 | 0.83 | PTPN5 (0.48) | MAPTPTGS2 | |
| SCHEMBL6135287 | 0.83 | SCN5A (0.42) | MAPTPTGS2HDAC3HDAC4HDAC1 | |
| SCHEMBL6318628 | 0.83 | KDM4E (0.43) | MAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005082414-A2 | CONCOMITANT DRUGS OF A SULFONAMIDE AND ANOTHER THERAPEUTIC AGENT | ASTELLAS PHARMA INC. (JP) | 2005-09-09 | — | — | WO | claimed |
| US-20050197376-A1 | Concomitant drugs | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-09-08 | — | — | US | claimed |
| US-20050171185-A1 | Indole derivatives | FUJISAWA PHARMACEUTICAL CO., LTD., A JAPANESE CORPORATION | 2005-08-04 | — | — | US | claimed |
| EP-1070705-A1 | INDOLE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-01-24 | — | — | EP | claimed |
| WO-2005082414-A2 | CONCOMITANT DRUGS OF A SULFONAMIDE AND ANOTHER THERAPEUTIC AGENT | ASTELLAS PHARMA INC. (JP) | 2005-09-09 | — | — | WO | disclosed |
| US-20050197376-A1 | Concomitant drugs | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-09-08 | — | — | US | disclosed |
| US-20050171185-A1 | Indole derivatives | FUJISAWA PHARMACEUTICAL CO., LTD., A JAPANESE CORPORATION | 2005-08-04 | — | — | US | disclosed |
| EP-1070705-A1 | INDOLE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171185-A1 | Indole derivatives | PDE5A, IGFBP5, HTR5A | MAPT 3941/4885PTGS2 2111/4885KAT6A 851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.